News for Healthier Living
Advanced Age Does Not Limit the Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Chronic Kidney Disease
New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026 October 22-25.
October 24, 2026
November 1 2026October 30 2026October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026
|
|
|
|
|